Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $515.44 +0.17%
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.79, $0.26 better than the analyst estimate of $3.53. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.3 billion.
GUIDANCE:
Vertex Pharma sees Q1 2023 revenue of $9.55-9.7 billion, versus the consensus of $9.6 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Skillsoft (SKIL) Tops Q2 EPS by 14c; Offers Guidance
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
